Garrison Financial Corp lowered its holdings in shares of AbbVie Inc (NYSE:ABBV) by 3.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 71,653 shares of the company’s stock after selling 2,781 shares during the period. AbbVie comprises 3.6% of Garrison Financial Corp’s portfolio, making the stock its largest holding. Garrison Financial Corp’s holdings in AbbVie were worth $6,367,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Savant Capital LLC raised its position in shares of AbbVie by 1.3% in the second quarter. Savant Capital LLC now owns 61,132 shares of the company’s stock valued at $4,433,000 after buying an additional 793 shares during the last quarter. Princeton Capital Management Inc. acquired a new position in AbbVie during the second quarter worth approximately $1,394,000. Palisade Asset Management LLC increased its position in AbbVie by 17.9% during the second quarter. Palisade Asset Management LLC now owns 68,311 shares of the company’s stock worth $4,953,000 after purchasing an additional 10,381 shares during the last quarter. Beaton Management Co. Inc. acquired a new position in AbbVie during the second quarter worth approximately $528,000. Finally, Greatmark Investment Partners Inc. increased its position in AbbVie by 3.7% during the second quarter. Greatmark Investment Partners Inc. now owns 35,178 shares of the company’s stock worth $2,551,000 after purchasing an additional 1,242 shares during the last quarter. Institutional investors own 69.28% of the company’s stock.

Several equities analysts recently commented on the stock. Piper Jaffray Companies upped their price target on shares of AbbVie from $115.00 to $130.00 and gave the stock an “outperform” rating in a research report on Friday. Leerink Swann lowered shares of AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 price target for the company. in a research report on Monday. SunTrust Banks upped their price target on shares of AbbVie to $157.00 and gave the stock an “average” rating in a research report on Monday. BMO Capital Markets lowered shares of AbbVie from a “market perform” rating to an “underperform” rating and dropped their price target for the stock from $125.86 to $59.27 in a research report on Monday. Finally, Evercore ISI reaffirmed a “buy” rating and set a $144.00 price target on shares of AbbVie in a research report on Monday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $111.27.

In related news, SVP Timothy J. Richmond sold 87,040 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. Following the sale, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Severino sold 25,633 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the sale, the executive vice president now directly owns 114,922 shares in the company, valued at $10,881,964.18. The disclosure for this sale can be found here. Insiders sold 476,376 shares of company stock worth $45,580,873 over the last ninety days. 0.23% of the stock is currently owned by corporate insiders.

AbbVie Inc (NYSE:ABBV) opened at $122.31 on Tuesday. The firm has a market cap of $196,696.13, a price-to-earnings ratio of 37.18, a PEG ratio of 1.28 and a beta of 1.52. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 52 week low of $59.27 and a 52 week high of $125.86.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, January 26th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.44 by $0.04. The business had revenue of $7.74 billion during the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a net margin of 18.82% and a return on equity of 152.78%. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.20 earnings per share. analysts anticipate that AbbVie Inc will post 7.38 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “AbbVie Inc (NYSE:ABBV) Shares Sold by Garrison Financial Corp” was reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.mareainformativa.com/2018/01/30/abbvie-inc-abbv-shares-sold-by-garrison-financial-corp-updated-updated-updated.html.

AbbVie Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.